首先,不伤害:刻画致幻剂治疗潜在危害的责任
本文综述了致幻剂作为治疗手段的已知与潜在危害,包括持续性知觉障碍、诱发或加重躁狂或精神病性障碍风险、过度使用、误用与依赖、挑战性体验或「糟糕旅程」、神经可塑性潜力增加相关风险以及急性和累积性心血管效应,并呼吁继续开展研究与监测。
要点
- 致幻剂治疗研究需同时关注获益与潜在风险
- 已知与潜在危害包括持续性知觉障碍、诱发躁狂或精神病性障碍、过度使用与依赖、挑战性体验、神经可塑性相关风险及心血管效应
- 作者呼吁继续开展研究并给出进一步研究与监测的建议
核心结论
- 随着致幻剂作为治疗手段的兴趣、投资、倡导和研究呈指数增长,研究不仅需关注其获益,也需关注其潜在风险。
- 在广泛人群(包括临床试验通常排除的精神和躯体共病患者)中及在监管或控制较少的环境下应用时,对注意事项的理解会更多。
研究设计与样本
- 本文为综述,检索并汇总了关于致幻剂已知与潜在危害的文献。
主要发现
- 综述涵盖的已知与潜在危害包括持续性知觉障碍;诱发或加重躁狂或精神病性障碍起病风险;过度使用、误用和依赖;挑战性体验或「糟糕旅程」;神经可塑性潜力增加相关风险;急性和累积性心血管效应。
临床怎么用
- 作者呼吁继续开展研究,并给出了进一步研究与监测的建议。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The last few years have seen exponential growth in interest, investment, advocacy, and research into psychedelics as therapeutics. This reflects an optimism about the potential promise of psychedelics as therapeutics. As with all therapeutic interventions, research is needed not only into their benefits but also potential risks. Indeed, when substances with therapeutic potential are scrutinized over time, especially in broad populations with psychiatric and medical comorbidities typically excluded from clinical trials, and applied in less well-regulated or controlled settings, a greater understanding of the cautions emerges. Here, we review the literature on the known and potential harms, including enduring perceptual disturbances; triggering or enhancing the risk for onset of mania or psychosis; overuse, misuse, and dependence; challenging experiences or "bad trips"; risks associated with increased neuroplastic potential; and acute and cumulative cardiovascular effects. Each of these issues is addressed in this review, along with the call for continued research, including recommendations for further research and monitoring.
引用
- Ghaznavi S, Ruskin JN, Haggerty SJ, et al. Primum Non Nocere: The Onus to Characterize the Potential Harms of Psychedelic Treatment. Am J Psychiatry. 2025. PMID: 39741443. doi:10.1176/appi.ajp.20230914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。